VivoSeq
Ophthalmology

Geographic Atrophy

37

Pipeline Programs↗

16

Active Trials↗

18

Companies Involved↗

Geographic Atrophy is a moderately active landscape with 37 programs across 18 companies. The most active players are Johnson & Johnson, NGM Biopharmaceuticals, Inc, Novartis. 3 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

27/100

Mech. Concentration

13/100

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2N

NGM Biopharmaceuticals, Inc

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2A

ADARx Pharmaceuticals, Inc.

1 program

Phase 2E

Evergreen Therapeutics, Inc.

1 program

Phase 2G

Galimedix Therapeutics Inc

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

28 of 34 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody39%Protein / enzyme13%Peptide13%RNA therapy13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 97% of 39 pipeline programs.

Analysis

Trial Status

44

clinical trials

Completed21 · 48%
Recruiting11 · 25%
Terminated5 · 11%
Active, not recruiting4 · 9%
Withdrawn1 · 2%
Unknown status1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

44 trials

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
Recruiting·BBionic Sight LLC·Phase 1/2·NCT07158775·40 enrolled
SGLT2 Inhibitors in Geographic Atrophy
Recruiting·WWashington University School of Medicine·Phase 2·NCT07174687·70 enrolled
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Recruiting·GGalimedix Therapeutics Inc·Phase 2·NCT06659549·110 enrolled
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Recruiting·AADARx Pharmaceuticals, Inc.·Phase 2·NCT06990269·240 enrolled
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04292080·90 enrolled
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Recruiting·Regeneron logoRegeneron·Phase 1·NCT07230834·54 enrolled
Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Recruiting·AbbVie logoAbbVie·Preclinical·NCT07160179·66 enrolled
Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT06635148·274 enrolled
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Recruiting·Astellas logoAstellas·N/A·NCT06779773·500 enrolled
A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Recruiting·Sanofi logoSanofi·Preclinical·NCT07215234·104 enrolled
A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Recruiting·Roche logoRoche·Phase 2·NCT05626114·60 enrolled
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
Active, not recruiting·AAnnexon, Inc.·Phase 3·NCT06510816·659 enrolled
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Active, not recruiting·BBelite Bio, Inc·Phase 3·NCT05949593·429 enrolled
A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration
Active, not recruiting·Astellas logoAstellas·Approved·NCT06970665·17 enrolled
GALE: Pegcetacoplan Long-Term Extension in GA
Active, not recruiting·Apellis Pharmaceuticals logoApellis Pharmaceuticals·Phase 3·NCT05800001·1,250 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)